Catalyst Pharmaceuticals Files Q1 2025 10-Q
Ticker: CPRX · Form: 10-Q · Filed: 2025-05-07T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, financials, royalty
Related Tickers: CPRX
TL;DR
Catalyst Pharma's Q1 2025 10-Q is in. Check financials.
AI Summary
Catalyst Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial performance and business operations. Key financial details and operational highlights are presented in this filing, which covers the first quarter of 2025.
Why It Matters
This filing provides investors with an update on Catalyst Pharmaceuticals' financial health and operational progress during the first quarter of 2025, impacting investment decisions.
Risk Assessment
Risk Level: medium — The company operates in the pharmaceutical industry, which is subject to significant regulatory, research, and market risks.
Key Numbers
- More than $500 million and less than $750 million — Royalty (Potential royalty payment range)
- More than $10 million and less than $100 million — Royalty (Potential royalty payment range)
- More than $250 million and less than $500 million — Royalty (Potential royalty payment range)
Key Players & Entities
- CATALYST PHARMACEUTICALS, INC. (company) — Filer
- 20250331 (date) — Reporting Period End Date
- 20250507 (date) — Filing Date
- 355 ALHAMBRA CIRCLE (address) — Business Address
- CORAL GABLES (city) — Business Address City
- FL (state) — Business Address State
- 33134 (zip_code) — Business Address Zip
- RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMember (financial_metric) — Royalty amount category
- AgamreeMember (entity) — Related to royalty payments
- U.s.RightsForFycompaMember (entity) — Related to US rights for Fycopa
FAQ
What is the reporting period for this 10-Q filing?
The reporting period is for the quarter ended March 31, 2025.
What is the company's primary business address?
The company's business address is 355 Alhambra Circle, Suite 801, Coral Gables, FL 33134.
What is the SIC code for Catalyst Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code is 2834, for Pharmaceutical Preparations.
What specific royalty payment ranges are mentioned in the filing?
The filing mentions royalty ranges of 'More Than Five Hundred Million And Less Than Seven Hundred Fifty Million', 'More Than Ten Million And Less Than Hundred Million', and 'More Two Hundred And Fifty Million And Less Than Five Hundred Million'.
When did Catalyst Pharmaceuticals, Inc. have a public offering?
A public offering is noted with the date 2024-01-09.
From the Filing
0000950170-25-065652.txt : 20250507 0000950170-25-065652.hdr.sgml : 20250507 20250507160931 ACCESSION NUMBER: 0000950170-25-065652 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 92 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250507 DATE AS OF CHANGE: 20250507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33057 FILM NUMBER: 25921405 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 10-Q 1 cprx-20250331.htm 10-Q 10-Q 0001369568 --12-31 false Q1 3 5 5 http://catalystpharma.com/20250331#PresidentAndChiefExecutiveOfficerMember 6 years http://fasb.org/us-gaap/2024#LiabilitiesCurrent http://fasb.org/us-gaap/2024#LiabilitiesCurrent 0001369568 cprx:RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMember cprx:AgamreeMember 2025-01-01 2025-03-31 0001369568 cprx:U.s.RightsForFycompaMember cprx:RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember us-gaap:RoyaltyAgreementTermsMember srt:MaximumMember 2025-01-01 2025-03-31 0001369568 cprx:RoyaltyMoreTwoHundredAndFiftyMillionAndLessThanFiveHundredMillionMember cprx:AgamreeMember srt:MaximumMember 2025-01-01 2025-03-31 0001369568 cprx:PublicOfferingMember 2024-01-09 2024-01-09 0001369568 cprx:LicenseAndAcquiredIntangiblesForFycompaMember 2024-01-01 2024-03-31 0001369568 cprx:RoyaltyForAdditionalIndicationsAndMilestonesMember cprx:AgamreeMember 2025-03-31 0001369568 cprx:RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember cprx:U.s.RightsForFycompaMember srt:MaximumMember 2025-01-01 2025-03-31 0001369568 us-gaap:LeaseholdImprovementsMember srt:MaximumMember 2025-03-31 0001369568 cprx:AgamreeMember srt:MaximumMember cprx:RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember 2025-01-01 2025-03-31 0001369568 2024-07-11 0001369568 cprx:U.s.RightsForFycompaMember cprx:RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember srt:MaximumMember 2025-01-01 2025-03-31 0001369568 cprx:AgamreeMember cprx:RoyaltyMoreThanTwoBillionMember 2025-01-01 2025-03-31 0001369568 cprx:CalendarYears2022Through2025Member cprx:LicenseAndAssetPurchaseAgreementMember 2022-07-11 2022-07-11 0001369568 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001369568 cprx:U.s.RightsForFycompaMember srt:MinimumMember cprx:RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember 2025-01-01 2025-03-31 0001369568 srt:MinimumMember cprx:AgamreeMember cprx:RoyaltyMoreThanTwoBillionMember 2025-01-01 2025-03-31 0001369568 cprx:LicenseAgreementForRuzurgiMember 2022-07-11 2022-07-11 0001369568 us-gaap:RestrictedStockUnitsRSUMember 2025-03-31 0001369568 us-gaap:SoftwareDevelopmentMember 2024-12-31 0001369568 srt:MinimumMember cprx:LicenseAgreementForRuzurgiMember 2025-01-01 2025-03-31 0001369568 cprx:RoyaltyMoreSevenHundredAndFiftyMillionAndLessThanOneBillionMember cprx:AgamreeMember srt:MaximumMember 2025-01-01 2025-03-31 0001369568 cprx:U.s.RightsForFycompaMember cprx:RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember 2025-01-01 2025-03-31 0001369568 us-gaap:SalesRevenueNetMember cprx:CustomersMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-03-31 0001369568 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0001369568 cprx:OptionsToPurchaseCommonStockMember 2025-03-31 0001369568 2024-01-01 2024-03-31 0001369568 us-gaap:AccumulatedOther